APPLIED GENETIC TECHNOLOGIES CORP

2022 Q4 Form 10-Q Financial Statement

#000119312522289919 Filed on November 21, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.24M $90.52M
YoY Change -62.17% 35.91%
Cash & Equivalents $34.20M $90.52M
Short-Term Investments $0.00
Other Short-Term Assets $2.998M $2.871M
YoY Change 4.42% 43.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $37.24M $93.39M
YoY Change -60.12% 36.25%
LONG-TERM ASSETS
Property, Plant & Equipment $4.884M $7.632M
YoY Change -36.01% 76.91%
Goodwill
YoY Change
Intangibles $1.541M
YoY Change
Long-Term Investments $7.732M $7.969M
YoY Change -2.97% -1.21%
Other Assets $126.0K $121.0K
YoY Change 4.13% -19.87%
Total Long-Term Assets $20.09M $17.03M
YoY Change 18.03% -0.29%
TOTAL ASSETS
Total Short-Term Assets $37.24M $93.39M
Total Long-Term Assets $20.09M $17.03M
Total Assets $57.33M $110.4M
YoY Change -48.07% 28.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.043M $2.083M
YoY Change 94.1% 25.94%
Accrued Expenses $13.03M $15.18M
YoY Change -14.18% 34.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.532M $4.444M
YoY Change 114.49%
Total Short-Term Liabilities $26.60M $21.71M
YoY Change 22.55% 66.84%
LONG-TERM LIABILITIES
Long-Term Debt $6.812M $15.66M
YoY Change -56.5% 59.79%
Other Long-Term Liabilities $99.00K $3.518M
YoY Change -97.19% 29.43%
Total Long-Term Liabilities $99.00K $19.18M
YoY Change -99.48% 605.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.60M $21.71M
Total Long-Term Liabilities $99.00K $19.18M
Total Liabilities $39.69M $40.89M
YoY Change -2.93% 39.01%
SHAREHOLDERS EQUITY
Retained Earnings -$326.6M
YoY Change
Common Stock $344.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $54.00K
Shareholders Equity $17.65M $69.53M
YoY Change
Total Liabilities & Shareholders Equity $57.33M $110.4M
YoY Change -48.07% 28.96%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001273636
CY2022Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2022Q3 dei Document Type
DocumentType
10-Q
CY2022Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q3 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 dei Entity File Number
EntityFileNumber
001-36370
CY2022Q3 dei Entity Registrant Name
EntityRegistrantName
APPLIED GENETIC TECHNOLOGIES CORPORATION
CY2022Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3553710
CY2022Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
14193 NW 119th Terrace, Suite 10
CY2022Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Alachua
CY2022Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32615
CY2022Q3 dei City Area Code
CityAreaCode
386
CY2022Q3 dei Local Phone Number
LocalPhoneNumber
462-2204
CY2022Q3 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q3 dei Trading Symbol
TradingSymbol
AGTC
CY2022Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q3 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67632195
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y30D
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34241000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46366000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2998000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3195000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
37239000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
49561000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2921000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4884000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4714000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1541000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1433000
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
7732000
CY2022Q2 us-gaap Equity Method Investments
EquityMethodInvestments
7807000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2890000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3043000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126000
CY2022Q3 us-gaap Assets
Assets
57333000
CY2022Q2 us-gaap Assets
Assets
66684000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4043000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2911000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11753000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11727000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1276000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1271000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
9532000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
9298000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
26604000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
25207000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2530000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2780000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
6812000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
9122000
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3642000
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
98000
CY2022Q3 us-gaap Liabilities
Liabilities
39687000
CY2022Q2 us-gaap Liabilities
Liabilities
37207000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51011000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67632000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50957000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
68000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
51000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67686000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
344456000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
337894000
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
54000
CY2022Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
54000
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
256000
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
256000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326622000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308212000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
17646000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
29477000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57333000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66684000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12884000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12325000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4460000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4100000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
17344000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
16425000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17344000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16425000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
189000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
6000
CY2022Q3 us-gaap Interest Expense
InterestExpense
657000
CY2021Q3 us-gaap Interest Expense
InterestExpense
669000
CY2022Q3 agtc Costs Attributable To The Issuance Of Freestanding Warrants
CostsAttributableToTheIssuanceOfFreestandingWarrants
331000
CY2021Q3 agtc Costs Attributable To The Issuance Of Freestanding Warrants
CostsAttributableToTheIssuanceOfFreestandingWarrants
0
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
192000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-991000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-663000
CY2022Q3 agtc Income Loss From Continuing Operations Before Equity In Net Earnings Losses Of Affiliate
IncomeLossFromContinuingOperationsBeforeEquityInNetEarningsLossesOfAffiliate
-18335000
CY2021Q3 agtc Income Loss From Continuing Operations Before Equity In Net Earnings Losses Of Affiliate
IncomeLossFromContinuingOperationsBeforeEquityInNetEarningsLossesOfAffiliate
-17088000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-75000
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-31000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18410000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17119000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64911000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42823000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64911000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42823000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
29477000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
651000
CY2022Q3 agtc Issuance Of Common Stock And Accompanying Warrants Value
IssuanceOfCommonStockAndAccompanyingWarrantsValue
5928000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18410000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
17646000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
85808000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
810000
CY2021Q3 agtc Stock Issued During Period Value Stock Based Compensation Stock Option Purchases
StockIssuedDuringPeriodValueStockBasedCompensationStockOptionPurchases
26000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17119000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
69525000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18410000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17119000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
651000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
810000
CY2022Q3 agtc Expense For Shares Of Common Stock Issued To A Vendor
ExpenseForSharesOfCommonStockIssuedToAVendor
4000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
372000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
364000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
192000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
161000
CY2021Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
169000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
153000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
108000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-75000
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-31000
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-505000
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
224000
CY2022Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
456000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
135000
CY2022Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-245000
CY2021Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-195000
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
49000
CY2021Q3 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-15000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16037000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15936000
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
183000
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
545000
CY2022Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
121000
CY2021Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
70000
CY2022Q3 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0
CY2021Q3 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2000000
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-304000
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1385000
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9019000
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
355000
CY2021Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2022Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
71000
CY2022Q3 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2237000
CY2022Q3 agtc Payment Of Taxes Related To Share Based Payment Arrangement
PaymentOfTaxesRelatedToShareBasedPaymentArrangement
0
CY2021Q3 agtc Payment Of Taxes Related To Share Based Payment Arrangement
PaymentOfTaxesRelatedToShareBasedPaymentArrangement
45000
CY2022Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2021Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
12000
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7137000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9204000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14537000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46366000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
105052000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37162000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90515000
CY2022Q3 agtc Prepaid Assets Included In Accounts Payable
PrepaidAssetsIncludedInAccountsPayable
393000
CY2021Q3 agtc Prepaid Assets Included In Accounts Payable
PrepaidAssetsIncludedInAccountsPayable
0
CY2022Q3 agtc Cost Related To Purchase Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
CostRelatedToPurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
338000
CY2021Q3 agtc Cost Related To Purchase Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
CostRelatedToPurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
96000
CY2022Q3 agtc Costs For Intangible Assets Included In Accrued And Other Liabilities
CostsForIntangibleAssetsIncludedInAccruedAndOtherLiabilities
64000
CY2021Q3 agtc Costs For Intangible Assets Included In Accrued And Other Liabilities
CostsForIntangibleAssetsIncludedInAccruedAndOtherLiabilities
25000
CY2022Q3 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organization and Operations </div></div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">General</div></div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Applied Genetic Technologies Corporation (the “Company” or “AGTC”) was incorporated as a Florida corporation on January 19, 1999 and reincorporated as a Delaware corporation on October 24, 2003. The Company is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for people suffering from rare and debilitating ophthalmic, otologic and central nervous system diseases. </div><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has devoted substantially all of its efforts to research and development activities, including conducting clinical trials for its product candidates, and has not completed the development of any products. The Company has generated revenue from collaboration agreements, licensing of its intellectual property, sponsored research agreements and grants, but has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies in the biotechnology industry, including dependence on key individuals, the need to obtain additional capital necessary to fund the development of its product candidates, the risk of failure of ongoing or future clinical studies, the difficulties inherent in the development of commercially viable products, the development by the Company or its competitors of technological innovations, the protection of proprietary technology, compliance with government regulations and the ability to transition to large-scale production of products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Financial Condition </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022, the Company had (i) an accumulated deficit of $326.6 million and (ii) cash and cash equivalents of $34.2 million. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Management believes that there is presently insufficient funding available to allow the Company to generate data from its ongoing and planned clinical programs and fund currently planned research and discovery programs for a period exceeding one year from the date of this filing with the Securities and Exchange Commission. Additionally, management believes that the Company will incur losses and generate negative operating cash flows for the foreseeable future. As such, these circumstances collectively raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying Unaudited Condensed Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. The Company has funded its operations to date primarily through public offerings of its common stock and warrants to purchase its common stock, private placements of its preferred stock, collateralized borrowing and collaborations. </div> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The ability of an entity to continue as a going concern depends on, among other things, positive cash flows and the availability of suitable financing. In the current business environment, the Company is unable to: (i) raise new capital through equity or debt financings or other sources; (ii) enter into one or more strategic collaboration arrangements to provide an adequate and immediate cash infusion for its ongoing operations and its leased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-to-suit</div></div> manufacturing and quality control facility that is described in Note 8 to these Notes to Unaudited Condensed Financial Statements; (iii) renegotiate the terms and conditions of its long-term debt agreement that is described in Note 5 to these Notes to Unaudited Condensed Financial Statements; (iv) sufficiently reduce its expenditures on research and development activities and/or restructure the Company’s operations to extend its cash runway; and/or (v) otherwise significantly enhance and improve its financial position. As such, management is actively seeking to consummate the proposed merger that is described in Note 9 to these Notes to Unaudited Condensed Financial Statements; however, management may be unable to successfully close that pending transaction. If the proposed merger is not completed within a reasonable period of time, or at all, management will likely pursue an orderly wind down of the Company through bankruptcy </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">proceedings. </div></div></div>
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326600000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34200000
CY2022Q3 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP and guidelines from the Securities and Exchange Commission requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates. </div></div>
CY2022Q3 us-gaap Escrow Deposit
EscrowDeposit
2900000
CY2022Q3 agtc Restricted Cash Disbursed Maturity Term
RestrictedCashDisbursedMaturityTerm
P1Y
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34200000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2900000
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
200000
CY2022Q3 agtc Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
2
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5551000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.58
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4186000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.69
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1201000
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.4
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1467000
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.62
CY2022Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
24000
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
97000
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.95
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
234000
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.27
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
66000
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.53
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
348000
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.93
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6589000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5047000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.32
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3048000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2667000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.29
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.55
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8259
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8251
CY2022Q3 us-gaap Investments
Investments
0
CY2022Q2 us-gaap Investments
Investments
0
CY2022Q3 agtc Carrying Amount Of Variable Rate Long Term Debt Net Of Unamortized Debt Discounts And Deferred Financing Fees
CarryingAmountOfVariableRateLongTermDebtNetOfUnamortizedDebtDiscountsAndDeferredFinancingFees
16300000
CY2022Q2 agtc Carrying Amount Of Variable Rate Long Term Debt Net Of Unamortized Debt Discounts And Deferred Financing Fees
CarryingAmountOfVariableRateLongTermDebtNetOfUnamortizedDebtDiscountsAndDeferredFinancingFees
18400000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
200000
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1275
CY2022Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1125
CY2022Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.163
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
149000000
CY2022Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.148
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
149000000
CY2022Q3 agtc Business Acquisition Percentage Of Voting Interests Needed To Be Acquired
BusinessAcquisitionPercentageOfVotingInterestsNeededToBeAcquired
0.50
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3400000
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.3
CY2021Q1 agtc Maximum Number Of Stocks Acquired By Outstanding Warrants
MaximumNumberOfStocksAcquiredByOutstandingWarrants
8370786
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6
CY2022Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-02-01
CY2022Q1 agtc Class Of Warrant Or Right Aggregate Warrants Exercised
ClassOfWarrantOrRightAggregateWarrantsExercised
0
CY2022Q3 us-gaap Payments For Rent
PaymentsForRent
30400000
CY2022Q3 us-gaap Other Commitment
OtherCommitment
2800000

Files In Submission

Name View Source Status
agtc-20220930_pre.xml Edgar Link unprocessable
0001193125-22-289919-index-headers.html Edgar Link pending
0001193125-22-289919-index.html Edgar Link pending
0001193125-22-289919.txt Edgar Link pending
0001193125-22-289919-xbrl.zip Edgar Link pending
agtc-20220930.xsd Edgar Link pending
d397426d10q.htm Edgar Link pending
d397426dex311.htm Edgar Link pending
d397426dex312.htm Edgar Link pending
d397426dex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g397426g1117230358699.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
d397426d10q_htm.xml Edgar Link completed
agtc-20220930_lab.xml Edgar Link unprocessable
agtc-20220930_cal.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
agtc-20220930_def.xml Edgar Link unprocessable